Statinler Doz Bağımlı Olarak Depo-Bağımlı Ca2+ Girişini Baskılar
Öz
Anahtar Kelimeler
Destekleyen Kurum
Proje Numarası
Teşekkür
Kaynakça
- 1. Stancu C, Sima A. Statins: Mechanism of action and effects. J of Cellular and Molecular Medicine. 2001; 5: 378–87.
- 2. Moneta GL. A Randomized Trial of Rosuvastatin in the Pre-vention of Venous Thromboembolism. Yearb Vasc Surg. 2010;2010(18):301–3.
- 3. Tobert JA. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517–26.
- 4. Lennernäs H, Fager G. Pharmacodynamics and pharmacoki-netics of the HMG-CoA reductase inhibitors. Similarities and differences. Clinical Pharmacokinetics. 1997; 32: 403–25.
- 5. Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotro-pic effects of statins. Indian J Endocrinol Metab. 2015;19(5):554–62.
- 6. Gary PH. JBM. SCT et al. Regression of coronary artery disea-se as a result of intensive lipit-lowering theraphy in men with high levels of apolipoprotein B. New English J Med. 1990;323(16):1120–3.
- 7. Schachter M. Chemical, pharmacokinetic and pharmacody-namic properties of statins: An update. Fundamental and Clinical Pharmacology. 2005; 19: 117–25.
- 8. Middleton K, Fish DE. Calcium channel regulation in vascular smooth muscle cells: synergistic effects of statins and cal-cium channel blockers. Curr Rev Musculoskeletal Med. 2009: 2; 94–104.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Klinik Tıp Bilimleri
Bölüm
Araştırma Makalesi
Yazarlar
Yasin Gökçe
*
0000-0002-2811-0709
Türkiye
Erken Görünüm Tarihi
27 Nisan 2023
Yayımlanma Tarihi
27 Nisan 2023
Gönderilme Tarihi
24 Kasım 2022
Kabul Tarihi
1 Aralık 2022
Yayımlandığı Sayı
Yıl 2023 Cilt: 20 Sayı: 1